Form 4: KalVista Pharmaceuticals Insider Sells Shares
Statement of Changes in Beneficial Ownership
KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, reported a transaction involving the sale of shares to cover tax withholding obligations.
Summary
- Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, Inc., reported a transaction on May 18, 2026.
- This transaction involved the sale of 1,032 shares of common stock at a price of $26.76 per share.
- The sale was to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).
- Following this transaction, Mr. Audhya beneficially owns 143,934 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale is a standard "sell to cover" transaction for tax purposes and not indicative of a negative outlook on the company's stock.
Positives
- The sale was a "sell to cover" transaction to satisfy tax withholding obligations, indicating it was not a discretionary sale of stock.
- Mr. Audhya continues to hold a significant number of shares (143,934) after the transaction.
Negatives
- A portion of the company's stock was sold by a key executive.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Management Comments
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
- The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions, often related to RSU vesting and associated tax liabilities. The "sell to cover" nature of this transaction is common practice for executives to manage tax burdens without signaling a negative view of the company's prospects.
Stakeholder Impact
- Shareholders: The transaction is unlikely to have a significant impact as it is a standard tax-related sale by an executive and not a discretionary sale of stock.
Key Dates
| Date | Description |
|---|---|
| 05/17/2026 | Earliest transaction date reported and RSU settlement date. |
| 05/18/2026 | Date of stock sale transaction. |
| 05/19/2026 | Date of signature on the filing. |
Keywords
KalVista Pharmaceuticals, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Paul K. Audhya, KALV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.